Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Operations: 2019-2024

Historic Cash from Operations for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$65.2 million.

  • C4 Therapeutics' Cash from Operations fell 29.31% to -$31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.5 million, marking a year-over-year decrease of 32.63%. This contributed to the annual value of -$65.2 million for FY2024, which is 39.01% up from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Cash from Operations is -$65.2 million, which was up 39.01% from -$106.8 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Cash from Operations peaked at -$65.2 million during FY2024, and registered a low of -$106.8 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$105.9 million (2022), whereas its average is -$92.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 220.92% in 2020, then spiked by 39.01% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Cash from Operations stood at -$67.2 million in 2020, then fell by 29.32% to -$87.0 million in 2021, then fell by 21.82% to -$105.9 million in 2022, then decreased by 0.85% to -$106.8 million in 2023, then spiked by 39.01% to -$65.2 million in 2024.